49 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
the vast majority of ART treatments or procedures. IVF helps women achieve pregnancy by the collection of mature eggs in the ovaries, followed … as a result of our termination of approximately 70% of our employees as announced in September 2022, a majority of whom were responsible for research
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of a majority … and offer of indemnity, shall have failed to institute any such action, suit or proceeding and (v) during such 90 day period, the holders of a majority
F-3
EX-4.1
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
of shareholders shall make resolutions and proceed to elections by an absolute majority of the votes cast.
En cas de partage égal des voix, celle du … , and the absolute majority of the aggregate par value of the shares represented is necessary to:
1. la modification du but social;
1. amend the purpose
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
as a foreign private issuer, either (1) a majority of our common shares must be either directly or indirectly owned of record by non-residents … of the United States or (2)(a) a majority of our executive officers or directors may not be United States citizens or residents, (b) more than 50% of our assets
6-K
EX-99.2
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
our current status as a foreign private issuer, either (1) a majority of our common shares must be either directly or indirectly owned of record by non … -residents of the United States or (2)(a) a majority of our executive officers or directors may not be United States citizens or residents, (b) more
6-K
6dy g2xyn
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
778zi193 vgz
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
F-3
EX-4.1
w4jkj0s
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.3
3xs5nk
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.1
144vt8a3h1 hhpmewg
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K/A
EX-99.2
vckra 2nydaczuqvug
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
npc4c562p9ebhh51a
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
424B5
br0g kirq1hszgmlp8p6
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-99.1
xdc a6psmsni9
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K
EX-4.1
gqzffd
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-4.3
3tnrd8y
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am